Trials / Recruiting
RecruitingNCT07141589
Fentanyl Versus Ketorolac as an Adjuvant to Peribulbar Block for Anterior Segment Surgeries
Fentanyl Versus Ketorolac as an Adjuvant to Peribulbar Block for Anterior Segment Surgeries, A Prospective Double-blinded Randomized Controlled Study
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 168 (estimated)
- Sponsor
- Cairo University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to compare the efficacy of ketorolac and fentanyl as adjuvants to local anesthetics for anterior segment surgeries of the eye.
Detailed description
Regional anesthesia for eye surgery includes peribulbar, retrobulbar, and sub-Tenon's blocks. Peribulbar block is commonly used due to a lesser incidence of serious complications such as globe perforation and retrobulbar hemorrhage. Fentanyl is a synthetic opioid widely used as an adjuvant to local anesthetics to prolong its action and provide better postoperative analgesia. fentanyl fastens lid and globe akinesia and provides a better akinesia score. Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that reduces the release of inflammatory mediators such as prostaglandins, thereby reducing afferent sensitivities and finally reducing pain. It is devoid of narcotic analgesic adverse effects such as sedation, nausea, and respiratory depression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lidocaine + Bupivacaine + Hyaluronidase | Patients will receive a mixture of 3 ml lidocaine 2%, 3 ml bupivacaine 0.5%, and hyaluronidase 60 IU diluted in normal saline to a total volume of 8 ml. |
| DRUG | Fentanyl + Lidocaine + Bupivacaine + Hyaluronidase | Patients will receive a mixture of 3 ml lidocaine 2%, 3 ml bupivacaine 0.5%, and hyaluronidase 60 IU and fentanyl 20 μg diluted in normal saline to a total volume of 8 ml. |
| DRUG | Ketorolac + Lidocaine + Bupivacaine + Hyaluronidase | Patients will receive a mixture of 3 ml lidocaine 2%, 3 ml bupivacaine 0.5%, hyaluronidase 60 IU, and ketorolac 15 mg diluted in normal saline to a total volume of 8 ml. |
Timeline
- Start date
- 2024-08-25
- Primary completion
- 2025-11-25
- Completion
- 2025-11-25
- First posted
- 2025-08-26
- Last updated
- 2025-08-26
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT07141589. Inclusion in this directory is not an endorsement.